Healthcare
Monday, May 2, 2016
BRIEF-Alnylam Pharmaceuticals reports Q1 GAAP loss per share $1.21 including items
* Q1 earnings per share view $-1.05 -- Thomson Reuters
I/B/E/S
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment